

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

POSTPONEMENT OF DATE OF BOARD MEETING

Reference is made to the date of board meeting announcement of CANbridge Pharmaceuticals Inc. (the “**Company**”) dated March 18, 2025 in relation to the date of meeting of the board (the “**Board**”) of directors (the “**Directors**”) of the Company will be held on Friday, March 28, 2025 (the “**Board Meeting**”) for the purpose of, among other matters, considering and approving the annual results of the Company and its subsidiaries for the year ended December 31, 2024 (the “**2024 Annual Results**”) and its publication.

The Board hereby announces that as the Company wants to ensure that as many Directors could attend the Board Meeting to approve the 2024 Annual Results as possible, the date of Board Meeting will be postponed to Monday, March 31, 2025.

By Order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, March 27, 2025

As at the date of this announcement, the Board comprises Dr. James Qun Xue as executive director; Dr. Fangxin Li as non-executive director; and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive directors.